ABSTRACT

Objective: To explore the HDL cholesterol-raising capacity of Irbesartan (an antihypertensive drug) in rabbit’s serum.
Study Design: Laboratory-based experimental study.
Place and Duration of Study: The study was carried out at the Animal House of the National Institute of Health (NIH) Islamabad, Pakistan from January 2023 to November 2023.
Methods: This study was conducted on 18 rabbits divided into three groups with six rabbits in each. Leaving one group as a normal control, two out of three groups were made hypercholesterolemic by a high-cholesterol diet. Irbesartan was given to one of the hypercholesteremic groups for 30 days. Blood samples were taken for serum analysis of HDL cholesterol.
Results: Results of blood serum levels of all three groups were compared and analyzed on three different occasions i.e., on day zero, day 120, and day 150 for HDL cholesterol. Their means were calculated using SPSS Version 20. The irbesartan-treated group showed obvious elevation in serum HDL cholesterol in comparison with the hypercholesteremic control group.
Conclusion: It is concluded that Irbesartan, an antihypertensive drug has an additional role of elevating serum high-density lipoproteins and can provide the supplementary benefit of improving the lipid profile in hypertension and Hypercholesterolemia.

Keywords: HDL, Hypercholesterolemia, Irbesartan.

How to cite this: Shakir S, Chaudhry ZR, Atif M, Sadaf R, Chaudhry ER, Chaudhry SR. Novel Role of Irbesartan in Elevating Serum High Density Lipoprotein in Hypercholesterolemic Animal Model. Life and Science. 2024; 5(2): 199-203. doi: http://doi.org/10.37185/LnS.1.1.536